Last reviewed · How we verify

Metformin, glyburide and insulin

Université de Sherbrooke · Phase 3 active Small molecule

Metformin, glyburide and insulin is a Antidiabetic combination therapy (biguanide + sulfonylurea + insulin) Small molecule drug developed by Université de Sherbrooke. It is currently in Phase 3 development for Type 2 diabetes mellitus.

This combination therapy addresses type 2 diabetes through three complementary mechanisms: metformin reduces hepatic glucose production, glyburide stimulates pancreatic insulin secretion, and insulin provides direct glucose-lowering action.

This combination therapy addresses type 2 diabetes through three complementary mechanisms: metformin reduces hepatic glucose production, glyburide stimulates pancreatic insulin secretion, and insulin provides direct glucose-lowering action. Used for Type 2 diabetes mellitus.

At a glance

Generic nameMetformin, glyburide and insulin
SponsorUniversité de Sherbrooke
Drug classAntidiabetic combination therapy (biguanide + sulfonylurea + insulin)
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

Metformin is a biguanide that decreases hepatic gluconeogenesis and improves insulin sensitivity. Glyburide is a sulfonylurea that stimulates beta cells to release endogenous insulin. Insulin provides exogenous glucose control. Together, these agents target multiple pathways in diabetes pathophysiology—hepatic glucose output, endogenous insulin secretion, and peripheral glucose uptake.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Metformin, glyburide and insulin

What is Metformin, glyburide and insulin?

Metformin, glyburide and insulin is a Antidiabetic combination therapy (biguanide + sulfonylurea + insulin) drug developed by Université de Sherbrooke, indicated for Type 2 diabetes mellitus.

How does Metformin, glyburide and insulin work?

This combination therapy addresses type 2 diabetes through three complementary mechanisms: metformin reduces hepatic glucose production, glyburide stimulates pancreatic insulin secretion, and insulin provides direct glucose-lowering action.

What is Metformin, glyburide and insulin used for?

Metformin, glyburide and insulin is indicated for Type 2 diabetes mellitus.

Who makes Metformin, glyburide and insulin?

Metformin, glyburide and insulin is developed by Université de Sherbrooke (see full Université de Sherbrooke pipeline at /company/universit-de-sherbrooke).

What drug class is Metformin, glyburide and insulin in?

Metformin, glyburide and insulin belongs to the Antidiabetic combination therapy (biguanide + sulfonylurea + insulin) class. See all Antidiabetic combination therapy (biguanide + sulfonylurea + insulin) drugs at /class/antidiabetic-combination-therapy-biguanide-sulfonylurea-insulin.

What development phase is Metformin, glyburide and insulin in?

Metformin, glyburide and insulin is in Phase 3.

What are the side effects of Metformin, glyburide and insulin?

Common side effects of Metformin, glyburide and insulin include Hypoglycemia, Gastrointestinal disturbance (metformin), Weight gain (insulin, glyburide), Lactic acidosis (metformin, rare).

Related